2019 New Origin Forum: The First Hangzhou Bay Biopharmaceutical Innovation Conference and the 5th BiG Impact Annual Meeting Successfully Concluded in Hangzhou
The biopharmaceutical industry is hailed as “the world’s evergreen sunrise industry” and has been prioritized as a strategic emerging sector by many countries. Over the next two decades, it may well become the next engine driving socioeconomic development and a high ground in international competition. On October 28, 2019, the 2019 New Force Forum·Inaugural Hangzhou Bay Biopharmaceutical Innovation Conference and the 5th Annual Impact Meeting of the Biopharmaceutical Innovation Society was held at the Hangzhou International Expo Center (G20 Summit Venue). Where do the frontier technologies and development trends in biopharma lie? How should the industry seize opportunities and address challenges? Industry experts from academia, medicine, industry, and investment worldwide—including Nobel laureates, industry leaders, academicians from China and the United States, and prominent venture capital investors—gathered to discuss these questions.
Hosted by the People's Government of Xiaoshan District, Hangzhou City, with coordination from the Hangzhou Investment Promotion Bureau, and organized by the Administrative Committee of Hangzhou Airport Economic Zone and the Xiaoshan District Bureau of Economy and Information Technology, the conference was executed by Zhejiang Jianxin Yuanli Pharmaceutical Co., Ltd. and the Biomedical Innovation Society. The event featured three keynote speeches by global pharmaceutical leaders, five forums on trending topics, and three specialized closed-door sessions, deeply focusing on emerging technologies and new models in the biomedical sector, as well as hot topics such as dual filing regulations in China and the United States, achievement transformation, and venture capital investment.
At the opening ceremony, Zhang Dengfeng, Secretary of the Party Leadership Group and Acting District Mayor of Xiaoshan District, pointed out that Xiaoshan has fully leveraged the window effect of its airport-based international cooperation and capitalized on the air-transport-oriented demands of biopharmaceutical industrialization. The clustered development of the biopharmaceutical sector has begun to yield initial results. Moving forward, the district will intensify efforts to develop the bioeconomy, focusing on high-quality, competitive, and modernized growth to vigorously advance the industrialization of biopharmaceuticals in Xiaoshan.
Zhang Dengfeng, Party Group Secretary and Acting District Mayor of the Xiaoshan District People's Government
At the event, Luo Jun, Director of the Xiaoshan District Investment Promotion Bureau in Hangzhou, released on behalf of Xiaoshan District the “Xiaoshan District Bioeconomy Industry Development Plan,” which supports industrial development through multiple measures, including fostering R&D innovation, attracting industry talent, aggregating capital platforms, and improving service systems.
Luo Jun, Director of the Investment Promotion Bureau of Xiaoshan District, Hangzhou City
As the initiator of this forum, Dr. Yu Guoliang, Chairman of Jianxin Yuanli, extended warm congratulations on the successful holding of the New Yuanli Forum. He stated that the forum aims to bring together elites from the global academic, industrial, and investment communities, as well as government agencies, to jointly advance the development of biomedicine.
Yu Guoliang, Chairman of Jianxin Yuanli and Founder of the New Yuanli Forum
2017 Nobel Laureate in Physiology or Medicine Michael Rosbash Shares His Perspectives on Scientific Research, Offering a Glimpse into His Extraordinary Scientific Journey.
Michael Rosbash, Winner of the 2017 Nobel Prize in Physiology or Medicine
William J. Rutter, a member of the U.S. National Academy of Sciences and Chairman of Synergenics, delivered a keynote address titled “The Past, Present, and Future of Biotechnology.” He stated that the rise of the biopharmaceutical industry will make immeasurable contributions to humanity’s efforts in combating various diseases.
William J. Rutter, Member of the U.S. National Academy of Sciences and Chairman of Synergenics
Wang Xiaodong, a member of the U.S. National Academy of Sciences and founder of BeiGene, bridged the preceding discussions by sharing his journey in scientific entrepreneurship, ranging from his work at the National Institute of Biological Sciences, Beijing, to his own research experiments.
Xiaodong Wang, Member of the U.S. National Academy of Sciences and Founder of BeiGene
Dr. Yingfei Wei, Chief Scientific Officer of Jianxin Yuanli, is a dedicated practitioner of public welfare initiatives. Under her leadership, the conference specially invited Professor Scott Rozelle from Stanford University and the “Dan Dang Zhe” Association to deliver public welfare speeches, rallying compassion and supporting charitable causes.
Wei Yingfei, Chief Scientific Officer of Jianxin Yuanli
Scott Rozelle, Professor at Stanford University
“Takers’ Movement” Association
The afternoon forum focused on global cooperation in biotechnology, moderated by Kenneth Carter, Senior Vice President of Global Cooperation at Jianxin Yuanli. Six distinguished guests delivered insightful academic presentations and participated in a panel discussion, exploring topics such as the current domestic and international landscape and development trends of the biomedical industry, as well as cutting-edge technologies and innovative R&D strategies.
Morrie Ruffin, Co-founder of the Regenerative Medicine Alliance
Terry Pearson, Professor at the University of Victoria, Canada
Bart Van Hooland, Founding Partner of Droia, Belgium
President of the China Pharmaceutical Innovation Promotion Association, Song Ruilin
Roundtable: Keeping Pace with the Advances of Chinese Biopharmaceuticals
Kenneth Carter, Senior Vice President of Global Partnerships at Jianxin Yuanli (left); Yu Changhai, Chairman of the Hong Kong Biotechnology Organization (center); and Lukas Utiger, Thermo Fisher Scientific’s Strategic Pharma Services Group for Asia (right)